Publishing research using ab74290? Please let us know so that we can cite the reference in this datasheet.
ab74290 has been referenced in 8 publications.
- Zhou L et al. Brefeldin A inhibits colorectal cancer growth by triggering Bip/Akt-regulated autophagy. FASEB J 33:5520-5534 (2019). PubMed: 30668917
- Zhang L et al. miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR. Onco Targets Ther 11:5293-5302 (2018). PubMed: 30214235
- Gao F et al. STARD13 is positively correlated with good prognosis and enhances 5-FU sensitivity via suppressing cancer stemness in hepatocellular carcinoma cells. Onco Targets Ther 11:5371-5381 (2018). PubMed: 30214243
- Ding J et al. Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma. BMB Rep 51:630-635 (2018). PubMed: 30293547
- Li JW et al. Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells. Biomed Pharmacother 104:204-210 (2018). WB ; Human . PubMed: 29772441
- Zhang Y et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 9:743 (2018). PubMed: 29970890
- Liu B et al. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway. J Exp Clin Cancer Res 37:316 (2018). PubMed: 30547804
- Nguyen A et al. Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition. Oncotarget 8:71597-71617 (2017). PubMed: 29069732